Drug Profile
Desmopressin - Elea
Alternative Names: DDAVPLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Elea
- Class Antidiuretics; Antihaemorrhagics; Hormones; Peptides; Urologics; Vasoconstrictors; Vasopressins
- Mechanism of Action Vasopressin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cancer metastases; Haemorrhage
Most Recent Events
- 20 Sep 2017 Desmopressin is at phase II development stage for Haemorrhage (in patients with colorectal cancer with rectal bleeding) in Argentina (IV)
- 01 Aug 2017 Elea completes a phase II trial in Haemorrhage (in patients with colorectal cancer with rectal bleeding) in Argentina (IV) (NCT01623206)
- 31 Jul 2015 Elea completes a phase II trial in Cancer metastases (Prevention) in Argentina (IV) (NCT01606072)